Benzo[a]pyrene metabolite concentrations in the gall bladder increased concomitantly with the depletion of BaP in the water.
The mortality from transitional cell carcinoma of the urinary bladder increases significantly with the progression of superficial to invasive disease.
When we examined the association between bladder cancer incidence and increasing levels of pioglitazone exposure (Table 2), the risk of bladder cancer slightly increased with increasing dose and duration of pioglitazone use.
Their further works identified α-defensin as one of the biomarkers, and expression of α-defensin peptides in bladder cancer cells increased with tumor invasiveness.
Using this threshold, the sensitivity of MCM-2 testing increased with bladder cancer grade (being 50% for grade 2 and 100% for grade 3) and stage (50% for pTa, and 100% for pT2), although numbers in each category were small (Supplementary Table 2).
A recent cohort study recruiting 79280 Swedish men hospitalized for BPH from 1964 to 1983 and following the patients until 1989 concluded that the overall risk of bladder cancer was not increased with BPH, but patients who underwent transurethral resection of the prostate had a significantly 47% higher risk [ 7].
Using this threshold, the sensitivity of MCM-2 testing increased with bladder cancer grade, being 75% for grade 1, 80% for grade 2 and 100% for grade 3, although it should be noted that numbers in each category were small (Supplementary Table 2).
A large study which assessed cyclin D1 localisation was performed with 150 transitional cell carcinomas of the bladder, wherein cytoplasmic cyclin D1 increased with disease progression and correlated with decreased survival (Tut et al, 2001).
Kershen et al. [ 16] showed that the urinary blood flow is increased with the increase in bladder pressure and volume, while Kroyer et al. [ 17] reported inconsistent variations in mucosal and muscular blood flow of the bladder with increased bladder pressure in dogs.
The p53 positivity increased with increasing grade while cerbB-2 positivity decreased with increasing grade of gall bladder cancer.
